
    
      This study is to assess the efficacy and safety of Rosuvamibe® (rosuvastatin 5mg/ezetimibe
      10mg) vs Monorova® (rosuvastatin 10mg) treated for 8 weeks in Korean patients with type 2
      diabetes mellitus and hypercholesterolemia.
    
  